Triangle of AKT2, miRNA, and Tumorigenesis in Different Cancers

被引:28
作者
Honardoost, Maryam [1 ]
Rad, Seyed Mohammad Ali Hosseini [2 ]
机构
[1] Iran Univ Med Sci, Inst Endocrinol & Metab, Endocrine Res Ctr, Mol Med, 10 Firoozeh St, Tehran, Iran
[2] Univ Otago, Dept Microbiol & Immunol, Dunedin, New Zealand
关键词
AKT signaling; AKT2; microRNAs; Cancer; HEPATOCELLULAR-CARCINOMA; BLADDER-CANCER; INHIBITS PROLIFERATION; MIR-612; SUPPRESSES; INSULIN-RESISTANCE; TUMOR-SUPPRESSOR; OVARIAN-CANCER; EXPRESSION; CELLS; MIGRATION;
D O I
10.1007/s12010-017-2657-3
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
AKT (AK mouse plus Transforming or Thymoma) is a frequent oncogene expressed in most tissues which includes three isoforms AKT1, AKT2, and AKT3. Hyperactivation of AKT signaling is a central key in many human cancer progressions, through modulating angiogenesis, tumor growth, and cell migration, invasion, metastasis, and chemoresistance. Among all three isoforms, AKT2 is most related to cancer cell invasion, metastasis, and survival. Amplification and overexpression of AKT2 have been shown in many cancers. Accumulating evidence shows the potential role of different miRNA involvements in cancer progression by activating or suppressing AKT2 expression. In an in-depth literature review, we focus on the role of AKT2 activation and its consequences on the tumor progression in different cancers. In addition, we describe the function of numerous AKT2-related miRNAs which are important in various cancers as diagnostic, prognostic, and therapeutic markers.
引用
收藏
页码:524 / 540
页数:17
相关论文
共 87 条
[1]   Akt1 and-2 inhibition diminishes terminal differentiation and enhances central memory CD8+ T-cell proliferation and survival [J].
Abu Eid, Rasha ;
Friedman, Kevin M. ;
Mkrtichyan, Mikayel ;
Walens, Andrea ;
King, William ;
Janik, John ;
Khleif, Samir N. .
ONCOIMMUNOLOGY, 2015, 4 (05)
[2]   AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth [J].
Altomare, DA ;
Wang, HQ ;
Skele, KL ;
De Rienzo, A ;
Klein-Szanto, AJ ;
Godwin, AK ;
Testa, JR .
ONCOGENE, 2004, 23 (34) :5853-5857
[3]  
[Anonymous], ONCOTARGET
[4]  
Archewa P, 2015, J INVESTIGATIVE CLIN
[5]  
Bai Y, 2015, INT J CLIN EXP MED, V8, P3801
[6]   MicroRNA-21 suppresses PTEN and hSulf-1 expression and promotes hepatocellular carcinoma progression through AKT/ERK pathways [J].
Bao, Longlong ;
Yan, Yan ;
Xu, Can ;
Ji, Weidan ;
Shen, Shuwen ;
Xu, Gaoya ;
Zeng, Yong ;
Sun, Bin ;
Qian, Haihua ;
Chen, Lei ;
Wu, Mengchao ;
Su, Changqing ;
Chen, Jie .
CANCER LETTERS, 2013, 337 (02) :226-236
[7]   SomamiR: a database for somatic mutations impacting microRNA function in cancer [J].
Bhattacharya, Anindya ;
Ziebarth, Jesse D. ;
Cui, Yan .
NUCLEIC ACIDS RESEARCH, 2013, 41 (D1) :D977-D982
[8]  
Brognard J, 2001, CANCER RES, V61, P3986
[9]   Evaluation of the cost of cervical cancer at the National Institute of Oncology, Rabat [J].
Cheikh, Amine ;
El Majjaoui, Sanaa ;
Ismaili, Nabil ;
Cheikh, Zakia ;
Bouajaj, Jamal ;
Nejjari, Chakib ;
El Hassani, Amine ;
Cherrah, Yahya ;
Benjaafar, Noureddine .
PAN AFRICAN MEDICAL JOURNAL, 2016, 23
[10]   Genetic variations of the PI3K-AKT-mTOR pathway and clinical outcome in muscle invasive and metastatic bladder cancer patients [J].
Chen, Meng ;
Gu, Jian ;
Delclos, George L. ;
Killary, Ann M. ;
Fan, Zhen ;
Hildebrandt, Michelle A. T. ;
Chamberlain, Robert M. ;
Grossman, H. Barton ;
Dinney, Colin P. ;
Wu, Xifeng .
CARCINOGENESIS, 2010, 31 (08) :1387-1391